**­Cartilage-specific *Sirt6* deficiency represses IGF-1 and enhances osteoarthritis severity in mice.**

John A. Collins1,2, C. James Kim1, Ashley Coleman1, Abreah Little1, Matheus Moreira Perez1, Emily J. Clarke3, Brian O. Diekman2, Mandy J. Peffers3, Susan Chubinskaya4, Ryan E. Tomlinson1, Theresa A. Freeman1, Richard F. Loeser2.

1 Department of Orthopaedic Surgery, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA. 2 Division of Rheumatology, Allergy and Immunology and the Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 3 Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK. 4 Department of Pediatrics, Rush University Medical Center, Chicago, IL, USA.

**Corresponding author:**

John A. Collins

Department of Orthopaedic Surgery

Sidney Kimmel Medical College

Thomas Jefferson University

1015 Walnut Street, Philadelphia, PA, 19107

john.collins2@jefferson.edu

**Running title:** *Sirt6* deficiency increases osteoarthritis in mice.

**Competing interests:** none

**ABSTRACT**

**Objectives.** Prior studies noted that chondrocyte SIRT6 activity is repressed in older chondrocytes rendering cells susceptible to catabolic signaling events implicated in osteoarthritis (OA). This study aimed to define the effect of *Sirt6* deficiency on the development of post-traumatic and age-associated OA in mice.

**Methods.** Male cartilage-specific *Sirt6* deficient mice and *Sirt6* intact controls underwent destabilization of the medial meniscus (DMM) or sham surgery at 16-weeks of age and OA severity was analyzed at 6- and 10-weeks post-surgery. Age-associated OA was assessed in mice aged 12- and 18-months of age. OA severity was analyzed by microCT, histomorphometry and scoring of articular cartilage structure, toluidine blue staining, and osteophyte formation. SIRT6-regulated pathways were analyzed in human chondrocytes by RNA-sequencing, qRT-PCR, and immunoblotting.

**Results.** *Sirt6* deficient mice displayed enhanced DMM-induced OA severity and accelerated age-associated OA when compared to controls, characterized by increased cartilage damage, osteophyte formation and subchondral bone sclerosis. In chondrocytes, RNA-sequencing revealed that *SIRT6* depletion significantly repressed cartilage extracellular matrix (e.g. *COL2A1*) and anabolic growth factor (e.g. *IGF-1*)gene expression. Gain- and loss-of-function studies in chondrocytes demonstrated that SIRT6 depletion attenuated, whereas adenoviral overexpression or MDL-800-induced activation of SIRT6, promoted IGF-1 signaling by increasing phosphorylation of Aktser473.

**Conclusions.** SIRT6 deficiencyincreases post-traumatic and age-associated OA severity *in vivo*. SIRT6 profoundly regulated the pro-anabolic and pro-survival IGF-1/Akt signaling pathway and suggests that preserving the SIRT6/IGF-1/Akt axis may be necessary to protect cartilage from injury- or age-associated OA. Targeted therapies aimed at increasing SIRT6 function could represent a novel strategy to slow or stop OA.

**Keywords:** Sirtuin 6, articular cartilage, osteoarthritis, chondrocyte, aging, IGF-1

**INTRODUCTION**

The highly conserved NAD+ dependent family of sirtuin deacetylases and mono-ADP ribosyltransferases (sirtuins 1-7) are key epigenetic regulators that control age-associated cell signaling pathways and promote longevity in various model organisms (1-3). Efforts to elucidate the precise roles of the nuclear localized sirtuin 6 (SIRT6) in aging and disease have come to the fore since the finding that global loss of *Sirt6* in mice leads to a progeroid phenotype, metabolic dysfunction, and death within 4 weeks of birth (4). Conversely, transgenic overexpression of *Sirt6* governs metabolic signaling events during aging to extend lifespan in both male and female mice (5-7). Several lines of evidence demonstrate that SIRT6 regulates an array of age-associated biological processes including DNA repair, cellular metabolism, oxidative stress, inflammation, autophagy, and senescence (1-3). As such, maintenance of SIRT6 activity during aging, or in response to stress, is considered important for the prevention of aging diseases such as cardiovascular disease, various metabolic and neurodegenerative disorders including diabetes and Alzheimer’s, certain cancers, and arthritis (1-3, 8, 9).

Age and joint injury are key risk factors for osteoarthritis (OA), which is the most common form of joint disease and a major cause of disability in the elderly (10, 11). Age-or injury-associated alterations that favor catabolic over anabolic signaling events in chondrocytes promote loss of extracellular matrix (ECM) components and are postulated to drive cartilage degradation in OA development and progression (10, 11). Recent evidence suggests that SIRT6 may be a critical regulator of these processes (8, 9, 12-14). For example, *in vitro* cell culture studies have shown that SIRT6 overexpression decreases replicative senescence, MMP-13 levels, and NF-ĸB regulated gene expression in human chondrocytes (12), whereas SIRT6 depletion increases markers of DNA damage and telomere dysfunction-induced foci in chondrocytes (14) and significantly represses *COL2A1* and *ACAN* gene expression in the chondrosarcoma SW1353 cell line (15). *In vivo* data in mice demonstrates that *Sirt6* haploinsufficiency increases cartilage proteoglycan loss and infrapatellar fat pad cytokine levels, resulting in higher OARSI scores in middle-aged mice on a high fat diet (16). In addition, myeloid-specific *Sirt6* deficiency in mice has been shown to increase joint inflammation and sensitivity to pro-catabolic FOXO1 signaling events to enhance joint inflammation in collagen-induced and K/BxN serum transfer models of rheumatoid arthritis (17). Conversely, intra-articular administration of adeno-associated virus or lentiviral SIRT6, to increase SIRT6 levels within the joint space, provides protection against cartilage damage in young mice receiving DMM surgery (8, 12).

Our previous study in primary human chondrocytes demonstrated that activation of SIRT6 promotes resistance to oxidative stress via increasing antioxidant protein levels, decreasing pro-oxidant TXNIP levels, and rapidly detoxifying nuclear generated H2O2 (9). In addition, activating SIRT6 significantly reduced oxidative stress induced catabolic NFĸB signaling events that are implicated in chondrocyte cell death and OA (9). Importantly, our report also showed that chondrocyte SIRT6 activity significantly declines with age in human articular chondrocytes (9). The effect of SIRT6 deficiency within the joint, and how this could contribute to cartilage damage and OA *in vivo*, however, remain largely unexplored. As prior studies investigating the role of *Sirt6* *in vivo* have utilized small numbers of experimental mice (n=4-6) (8, 12), the aim of this study was to comprehensively define the effects of *Sirt6* deficiency on OA. As injury and age represent two major risk factors for OA, we examined the effect of *Sirt6* deficiency on younger mice given destabilization of the medial meniscus surgery as a model of post-traumatic OA, and also assessed spontaneous, naturally occurring OA severity in middle-aged (12-month-old) and older (18-month-old) mice. The specific mechanisms by which SIRT6 regulates chondrocyte function to protect cartilage from OA was examined in these mice as well as *in vitro* using primary human chondrocytes.

**MATERIALS AND METHODS**

Detailed experimental procedures and analyses are provided in supplemental files.

**RESULTS**

**Cartilage specific *Sirt6* deficiency increases DMM-induced OA severity in mice.** As global loss of *Sirt6* in mice results in death within 4 weeks of age (4), we generated inducible cartilage-specific *Sirt6* deficient mice (*Sirt6fl/fl;Aggrecan-CreERT2*, *Sirt6* cKO) and compared them to *Sirt6* intact littermate controls (*Sirt6fl/fl*). *Sirt6* intact and *Sirt6* deficient miceunderwent destabilization of the medial meniscus (DMM) surgery or sham surgery (18) at 16 weeks of age and OA severity was analyzed by histology, detailed histomorphometry, and microCT at 6- and 10-weeks post-surgery. We have previously demonstrated cartilage SIRT6 deficiency in this model *ex vivo* (9) which has been validated here by IHC (Supplementary figure 1). Histologically, both *Sirt6* intact and *Sirt6* deficient mice receiving DMM surgery developed signs of OA, characterized by significant increases in summed Articular Cartilage Structure (ACS), toluidine blue, osteophyte, and synovial hyperplasia scores when compared to sham controls at both time points studied (Figure 1A-D, Supplementary figure 2, 3). When comparing DMM groups (*Sirt6* intact vs. *Sirt6* cKO), ACS, toluidine blue, and osteophyte scores were significantly higher (worse) in *Sirt6* deficient mice when compared to *Sirt6* intact mice at 6- and 10-weeks post-surgery (Figure 1A-D, Supplementary figure 2, 3).

 In alignment with our histological data, detailed histomorphometric analysis of the medial and lateral tibial plateaus showed that mice receiving sham surgery displayed little signs of OA whereas DMM surgery produced an OA phenotype at both time points studied, as evidenced by significant cartilage loss, and in some cases, loss of calcified cartilage and increased subchondral bone plate (SCBP) area and thickness (Table 1, 2, Supplementary table 2, 3). At 6-weeks post-surgery, *Sirt6* deficient mice receiving DMM surgery displayed significant reductions in articular cartilage area and thickness when compared to *Sirt6* intact mice receiving DMM surgery (Table 1, Supplementary table 2). At 10 weeks this OA phenotype was exacerbated and mice with cartilage specific *Sirt6* deficiencyalso displayed significant reductions in calcified cartilage thickness and enhanced SCBP area and thickness when compared to *Sirt6* intact mice undergoing DMM (Table 2, Supplementary table 3).

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Parameter** | ***Sirt6* intact****sham**Mean (SD)  | ***Sirt6* intact****DMM**Mean (SD) | ***Sirt6* cKO****sham**Mean (SD) | ***Sirt6* cKO****DMM**Mean (SD) | ***Sirt6* intact sham****vs*****Sirt6* intact DMM***p*-value | ***Sirt6* cKO sham****vs*****Sirt6* cKO DMM***p*-value | ***Sirt6* intact DMM****vs*****Sirt6* cKO DMM***p*-value |
| Art. Cart. Area(µm2) | 46,566(12,474) | 36,953(9,587) | 51,587(15,812) | 24,545(14,379) | **0.0478** | **0.0005** | **0.0136** |
| Art. Cart. Thickness(µm) | 47.15(10.56) | 34.76(9.88) | 48.42(12.60) | 17.60(11.01) | **0.0121** | **<0.0001** | **0.0003** |
| Calc. Cart. Area(µm2) | 43,407(8,996) | 43,694(10,658) | 37,507(6,625) | 53,603(14,998) | 0.9497 | **0.0070** | 0.0576 |
| Calc. Cart. Thickness(µm) | 41.95(7.61) | 38.55(7.08) | 42.45(7.04) | 34.60(7.64) | 0.3045 | **0.0240** | 0.1755 |
| SCBP Area(µm2) | 67,833(32,720) | 83,472(22,262) | 52,673(17,378) | 86,972(18,713) | 0.1963 | **0.0003** | 0.7723 |
| SCBP Thickness(µm) | 58.83(27.6) | 59.94(16.88) | 52.96(18.53) | 94.49(28.81) | 0.9077 | **0.0011** | **0.0112** |

**Table 1. Histomorphometric analysis of *Sirt6* intact and *Sirt6* deficient mice receiving DMM or sham surgery 6 weeks post-DMM surgery.** Histomorphometry measurements of articular cartilage (Art. cart) thickness and area, calcified cartilage (Calc. cart) thickness and area, and subchondral bone plate (SCBP) thickness and area were analyzed from mid coronal sections of mouse limbs (medial tibial plateau) from *Sirt6* intact and *Sirt6* deficient (cKO) mice receiving DMM or sham surgery 6 weeks post-DMM surgery. *Sirt6* intact sham: n=8; *Sirt6* intact DMM: n=14; *Sirt6* cKO sham: n=9; *Sirt6* cKO DMM: n=13. Results are presented as mean ± standard deviation (SD). Significant differences between groups were detected by Mann-Whitney test comparing sham and DMM groups for each genotype. Exact *p-*values are presented.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Parameter** | ***Sirt6* intact****sham**Mean (SD) | ***Sirt6* intact****DMM**Mean (SD) | ***Sirt6* cKO****sham**Mean (SD) | ***Sirt6* cKO****DMM**Mean (SD) | ***Sirt6* intact sham****vs*****Sirt6* intact DMM***p*-value | ***Sirt6* cKO sham****vs*****Sirt6* cKO DMM***p*-value | ***Sirt6* intact DMM vs*****Sirt6* cKO DMM***p*-value |
| Art. Cart. Area(µm2) | 50,027(7,337) | 36,080(12,399) | 43,670(10,566) | 15,334(12.933) | **0.0078** | **0.0002** | **0.0001** |
| Art. Cart. Thickness(µm) | 46.47(5.41) | 30.87(9.83) | 36.43(6.52) | 12.88(11.27) | **0.0005** | **0.0002** | **<0.0001** |
| Calc. Cart. Area(µm2) | 57,312(16,946) | 56,891(7,969) | 60,243(6,928) | 45,417(22,057) | 0.9348 | 0.1290 | 0.0686 |
| Calc. Cart. Thickness(µm) | 44.58(9.50) | 46.66(8.31) | 47.60(3.87) | 35.73(16.33) | 0.5904 | 0.1000 | **0.0296** |
| SCBP Area(µm2) | 66,156(22,032) | 95,316(23,622) | 79,749(30,296) | 127,842(36,678) | **0.0089** | **0.0115** | **0.0081** |
| SCBP Thickness(µm) | 49.37(12.37) | 76.01(19.7) | 55.14(9.53) | 103.10(36.47) | **0.0024** | **0.0058** | **0.0185** |

**Table 2. Histomorphometric analysis of *Sirt6* intact and *Sirt6* deficient mice receiving DMM or sham surgery 10 weeks post-DMM surgery.** Histomorphometry measurements of articular cartilage (Art. cart) thickness and area, calcified cartilage (Calc. cart) thickness and area, and subchondral bone plate (SCBP) thickness and area were analyzed from mid coronal sections of mouse limbs (medial tibial plateau) from *Sirt6* intact and *Sirt6* deficient (cKO) mice receiving DMM or sham surgery 10 weeks post-DMM surgery. *Sirt6* intact sham: n=8; *Sirt6* intact DMM: n=15; *Sirt6* cKO sham: n=6; *Sirt6* cKO DMM: n=14. Results are presented as mean ± standard deviation (SD). Significant differences between groups were detected by Mann-Whitney test comparing sham and DMM groups for each genotype. Exact *p-*values are presented.

MicroCT analysis of BV/TV, Tb.Th, Tb.Sp, and SCBP.Th was conducted on the medial tibial plateaus of all mice. At 6-weeks post-surgery, *Sirt6* deficient mice receiving DMM surgery exhibited significant increases in BV/TV and Tb.Th and significantly lower Tb.Sp values, indicating enhanced bone sclerosis in this group when compared to *Sirt6* deficient mice receiving sham surgery (Figure 1E,G). No changes were observed between *Sirt6* intact mice from either surgery group at this time point. At 10 weeks post-surgery, both DMM groups displayed increases in BV/TV and Tb.Th and significantly lower Tb.Sp when compared to sham mice, indicating DMM-induced bone sclerosis at this time point (Figure 1F,H). When analyzing differences between DMM groups, *Sirt6* deficient mice displayed significant increases in BV/TV and Tb.Th, and reductions in Tb.Sp when compared to *Sirt6* intact mice, suggesting enhanced bone sclerosis in the absence of *Sirt6* (Figure 1F,H). Osteophyte area and osteophyte volume were also significantly greater in *Sirt6* deficient mice receiving DMM surgery when compared to *Sirt6* intact mice (Figure 1I-J), which aligns with our histological osteophyte scoring. Collectively, these data demonstrate that *Sirt6* deficiency in mouse cartilage increases the severity of DMM-induced OA.

**Cartilage specific *Sirt6* deficiency accelerates spontaneous age-associated OA severity in mice.** To assess the effect of *Sirt6* deficiency on spontaneous, naturally occurring OA, *Sirt6* intact and *Sirt6* deficient mice were aged to 12- and 18-months with OA severity analyzed as per our DMM study. At 12 months of age, *Sirt6* deficient mice displayed a significant increase in summed ACS, toluidine blue, and osteophyte scores, when compared to *Sirt6* intact controls (Figure 2 A,B). In agreement, detailed histomorphometric analysis showed that *Sirt6* deficient mice displayed significant reductions in articular and calcified cartilage area on both the medial and lateral side, when compared to *Sirt6* intact controls (Table 3,4). At 18 months, both genotypes displayed profound OA with almost complete loss of cartilage evident on the medial tibial plateaus, with no significant differences between genotypes (Figure 2, Table 3). On the lateral side, *Sirt6* deficient mice displayed a significant decrease in articular cartilage area and thickness when compared to *Sirt6* intact controls at 18 months of age (Table 4). Age or genotype had no effect on synovial hyperplasia in this aging study (Figure 2B). Similarly, we did not detect any significant differences by microCT on subchondral bone parameters (medial side) when analyzing limbs from either genotype at both time points (Figure 2 E,F). The finding that synovial hyperplasia and subchondral bone changes were not affected by aging aligns with our prior mouse studies assessing these parameters at similar time points (19-23). Immunohistochemistry to detect p16ink4a as a marker of senescence was performed on mouse joint tissue sections on 18-month-old *Sirt6* intact and *Sirt6*-deficient mice. *Sirt6* deficient mice displayed a significant increase in p16ink4a positive cells in the synovium when compared to *Sirt6* intact controls (*p*=0.0031)(Supplementary figure 4). Taken together, this data demonstrates that cartilage-specific *Sirt6* deficiency significantly accelerates spontaneous, age-associated OA in mice.

Of interest, when analyzing control mouse limbs from the 6 month old DMM cohort (10 weeks post sham surgery) and comparing them to 12- and 18- month old *Sirt6* intact controls, we observed an increase in BV/TV and Tb.Th values, and a reduction in Tb.Sp values in older mouse limbs. This finding suggests that aging alone in mice increases subchondral bone sclerosis, which, to the best of our knowledge is an original finding (Supplementary Figure 5).

|  |  |  |
| --- | --- | --- |
|  | **12 months** | **18 months** |
| **Parameter** | ***Sirt6* intact**Mean (SD) | ***Sirt6* cKO**Mean (SD) | ***Sirt6* intact****vs*****Sirt6* cKO***p-value* | ***Sirt6* intact**Mean (SD) | ***Sirt6* cKO**Mean (SD) | ***Sirt6* intact****vs*****Sirt6* cKO***p*-value |
| **Art. Cart. Area (µm2)** | 47,347(11,461) | 29,267(15,049) | **0.0009** | 32,247(22,148) | 25,679(17,330) | 0.3734 |
| **Art. Cart. Thickness (µm)** | 36.80(9.68) | 25.12(13.53) | **0.0112** | 22.80(17.34) | 22.84(14.68) | 0.9943 |
| **Calc. Cart. Area (µm2)** | 47,893(13,631) | 31,315(13,509) | **0.0024** | 38,813(12,620) | 30,779(14,969) | 0.1232 |
| **Calc. Cart. Thickness (µm)** | 37.14(7.41) | 29.06(10.8) | **0.0418** | 34.99(10.66) | 30.46(14.34) | 0.3354 |
| **SCBP Area (µm2)** | 84,978(30,744) | 121,943(46,803) | **0.0163** | 101,224(55,040) | 105,380(52,073) | 0.8333 |
| **SCBP Thickness (µm)** | 70.53(24.42) | 90.82(36.63) | 0.0851 | 83.78(34.08) | 74.15(25.48) | 0.3882 |

**Table 3. Histomorphometric analysis of *Sirt6* intact and *Sirt6* deficient mice at 12- and 18-months of age (medial tibial plateau).** Histomorphometry measurements of articular cartilage (Art. cart) thickness and area, calcified cartilage (Calc. cart) thickness and area, and subchondral bone plate (SCBP) thickness and area were analyzed from mid coronal sections of mouse limbs (medial tibial plateau) from *Sirt6* intact and *Sirt6* deficient (cKO) mice at 12- and 18-months of age (n=15). Results are presented as mean ± standard deviation (SD). Significant differences between groups were detected by Mann-Whitney test comparing sham and DMM groups for each genotype. Exact *p-*values are presented.

|  |  |  |
| --- | --- | --- |
|  | **12 months** | **18 months** |
| **Parameter** | ***Sirt6* intact**Mean (SD) | ***Sirt6* cKO**Mean (SD) | ***Sirt6* intact****vs*****Sirt6* cKO***p-value* | ***Sirt6* intact**Mean (SD) | ***Sirt6* cKO**Mean (SD) | ***Sirt6* intact****vs*****Sirt6* cKO***p*-value |
| **Art. Cart. Area (µm2)** | 47,487(14,995) | 37,086(7,835) | **0.0243** | 55,353(19,226) | 31,291(12,683) | **0.0004** |
| **Art. Cart. Thickness (µm)** | 35.41(10.69) | 31.33(5.88) | 0.2671 | 44.14(26.26) | 26.26(10.5) | **<0.0001** |
| **Calc. Cart. Area (µm2)** | 31,315(13,509) | 42,085(9,992) | **0.0279** | 40,181(9,089) | 34,257(8,501) | 0.0759 |
| **Calc. Cart. Thickness (µm)** | 33.96(7.33) | 27.94(7.63) | **0.0363** | 32.45(5.15) | 28.39(5.95) | 0.0554 |
| **SCBP Area (µm2)** | 66,076(22,920) | 69,915(18,988) | 0.6213 | 68,257(38,968) | 64,297(14,328) | 0.7146 |
| **SCBP Thickness (µm)** | 49.71(17.84) | 52.22(15.56) | 0.6854 | 44.95(14.05) | 44.54(10.14) | 0.9279 |

**Table 4. Histomorphometric analysis of *Sirt6* intact and *Sirt6* deficient mice at 12- and 18-months of age (lateral tibial plateau).** Histomorphometry measurements of articular cartilage (Art. cart) thickness and area, calcified cartilage (Calc. cart) thickness and area, and subchondral bone plate (SCBP) thickness and area were analyzed from mid coronal sections of mouse limbs (lateral tibial plateau) from *Sirt6* intact and *Sirt6* deficient (cKO) mice at 12- and 18-months of age (n=15). Results are presented as mean ± standard deviation (SD). Significant differences between groups were detected by Mann-Whitney test comparing sham and DMM groups for each genotype. Exact *p-*values are presented.

***Sirt6* deficiency is associated with downregulation of ECM and growth factor genes in human chondrocytes.** To define the effect of *SIRT6*-mediated transcriptional regulation, RNA-sequencing was conducted on primary human chondrocytes depleted of *SIRT6* and compared to cells nucleofected with a scrambled siRNA control (72 hours). Initial studies were undertaken to confirm *SIRT6* depletion and demonstrated that nucleofection of *SIRT6* siRNA led to a significant reduction in SIRT6 protein levels when compared to control (*p*=<0.0001) (Supplementary figure 6A). In our RNA-seq dataset, principal component analysis (PCA) demonstrated that groups were strongly clustered by treatment (Supplementary figure 6B). Comparison of *SIRT6* depleted samples to controls revealed that 236 genes were differentially expressed, with 160 genes being downregulated and 76 genes being upregulated (Figure 3A). Ingenuity Pathway Analysis (IPA) demonstrated that depletion of chondrocyte *SIRT6* was predicted to increase joint inflammation, cartilage damage, and the OA disease process (Supplementary figures 6C, 7). Analysis of gene ontology (GO) enrichment revealed that extracellular matrix (ECM), proteinaceous extracellular matrix (both cellular component), and growth factor activity (molecular function) terms were the top three repressed processes in human chondrocytes depleted of *SIRT6* when compared to controls (Figure 3B).

Interrogation of differentially expressed ECM genes revealed that *COL2A1*, the primary collagen found in articular cartilage, was significantly reduced in *SIRT6* depleted cells along with other ECM genes such as *COMP, ECM2, CILP2,* and *COL8A1.* In agreement, *COL2A1* (*p*=0.0008)and *COMP* (*p*=0.0001) gene expression were significantly reduced in *SIRT6* deficient chondrocytes, when compared to controls, as assessed by qRT-PCR (Figure 3C). In the context of growth factor repression, pro-anabolic insulin-like growth factor-1 (*IGF-1*) and its binding partner, IGF binding protein-2 (*IGFBP2*)were highly downregulated in *SIRT6* depleted chondrocytes, when compared to controls, which was validated by qRT-PCR (*IGF-1*; *p*=0.0070*,* *IGFBP-2*; *p*=0.0011). Upstream Regulator Analysis demonstrated that downregulation of *IGF-1* is predicted to repress various pro-anabolic cartilage genes identified in our dataset, which included *COL2A1* and *IGFBP2* (Figure 3D). Other notable downregulated genes in the RNA-seq dataset that were validated by qRT-PCR included *SIRT6* (*p*=0.0011), the Wnt inhibitors, *SFRP1* (*p*=0.0048) and *SFRP4* (*p*=0.0002), and the well described SIRT6-regulated metabolic and longevity regulator, *PCK1* (*p*=0.005) (Figure 3C). Conversely, deficiency of *SIRT6* led to a significant increase in pro-catabolic *IL1RL1* and *HHIP* genes, which, when enhanced, have been implicated in the progression and development of osteoarthritis (24, 25). These effects were also validated by qRT-PCR (*IL1RL1*; *p*=0.0121, *HHIP*; *p*=0.0008) (Figure 3A, C).

Taken together, these results demonstrate that loss of *SIRT6* significantly decreases *IGF-1* gene expression as well as a host of ECM matrix genes including *COL2A1* and promotes the gene expression of pro-catabolic genes associated with OA. As IGF-1 signaling plays a critical role in maintenance of the cartilage ECM as well as chondrocyte survival, these results stimulated us to explore the SIRT6/IGF-1 axis in chondrocytes further.

**SIRT6 regulates IGF-1 signaling in human chondrocytes.** To assess the effect of *Sirt6* deficiency on IGF-1 signaling in our mouse model, femoral cap cartilage derived from *Sirt6* intact and *Sirt6* deficient mice was dissected and cultured as explant cultures *ex vivo*. Explants were treated with 4-hydroxytamoxifen daily for 96 hours to induce Cre-mediated depletion of *Sirt6* and then chondrocytes were extracted and processed for immunoblotting to detect IGFBP2, and phosphorylated Akt, as a marker of IGF-1 signal pathway activation. *Sirt6* depleted explants displayed a significant reduction in basal IGFBP2 (*p*=0.0112) and phospho-Aktser473 (*p*=0.0229) protein levels when compared to *Sirt6* intact femoral cap explants (Figure 4A). IHC performed on joint tissue sections derived from *Sirt6* intact and *Sirt6* deficient sham control mice from our DMM study demonstrated that IGF-1 levels were significantly decreased in *Sirt6* deficient mouse cartilage when compared to *Sirt6* intact controls (*p*=0.0002), which aligns with our RNA-sequencing data in human chondrocytes with *Sirt6* knockdown (Figure 4B).

 As *Sirt6* deficiency decreased the IGF-1/Akt axis in mouse cartilage, we next aimed to test the effect of SIRT6 activation to promote IGF-1 signaling in chondrocytes. Primary human chondrocytes were transduced with an adenoviral vector encoding *SIRT6* (24 hrs.) to increase SIRT6 activity, or an empty vector (null) control as we have previously described (9). Overexpression of SIRT6 significantly increased basal phosphorylation of Akt at Ser473 (*p*=0.0178) and Thr308 (*p*=0.0003) and increased phosphorylation of proline-rich Akt substrate (PRAS40) (*p*=0.0249), a marker of Akt activity (26, 27), when compared to null empty vector controls (Figure 4C). Next, we treated primary human chondrocytes with the small molecule activator of SIRT6, MDL-800, that has been previously shown by others to increase SIRT6 activity up to 22-fold (28). We isolated chondrocyte histones and performed immunoblotting for the acetylated form of the SIRT6 substrate, H3K9 (H3K9ac), an inverse marker of SIRT6 activity (9). Treatment of chondrocytes with MDL-800 (12.5 µM, 24 hrs.) led to a significant decrease in the basal acetylated form of H3K9 (*p*=0.0001), indicating enhanced SIRT6 activity compared to controls (Supplementary figure 8). In total cell lysates, MDL-800-induced SIRT6 activation led to a significant increase in basal phospho-Aktser473 and phospho-PRAS40 that peaked at 3 hours of treatment (*p*=0.0170, *p*=0.0120, respectively) (Figure 4D). SIRT6 protein levels did not change in response to treatment with MDL-800 over the time course studied, which is in accordance with others (28, 29). Collectively, these gain- and loss-of-function studies demonstrate that SIRT6 is a critical regulator of the pro-anabolic IGF-1 signaling pathway in mouse and human chondrocytes and decreases catabolic signaling events associated with OA.

**DISCUSSION**

This study demonstrates that *Sirt6* deficiency in the cartilage significantly enhances OA severity in response to DMM surgery in younger mice and accelerates spontaneous OA in older mice, characterized by profound cartilage degradation, subchondral bone sclerosis, and osteophyte formation. Mechanistically, RNA sequencing analysis revealed that *SIRT6* depletion in chondrocytes significantly repressed *IGF-1* gene expression and a plethora of cartilage ECM associated genes including *COL2A1*. Further, qRT-PCR, immunohistochemistry, and immunoblotting analyses demonstrated that downregulation of SIRT6 significantly represses *IGF-1* and the IGF-1/Akt signaling pathway, whereas SIRT6 overexpression, or activation using MDL-800, significantly increases Akt activity.

Our finding that cartilage specific *Sirt6* deficiency increased OA in mice agrees with a recently published manuscript by Ji et al (8) which demonstrated that mouse chondrocytes depleted of *Sirt6* display upregulated catabolic IL-15/JAK/STAT signaling, leading to senescence and enhanced OA *in vivo* (8). Our finding that that p16ink4a levels were significantly increased in the synovium of old *Sirt6*-deficient mice, when compared to controls, aligns with this concept and suggests that cartilage damage as a result of *Sirt6* deficiency could promote the release of catabolic factors that are released into the joint to promote senescence. Alongside these lines of data, prior findings conducted in chondrocytes report that SIRT6 abrogates NFκB signaling (9, 12), enhances DNA repair pathways (14), and promotes resistance to oxidative stress conditions (9). Along with our finding that *Sirt6* critically regulates IGF-1 signaling, this data demonstrates that SIRT6, which is positioned at the apex of many important age- and OA-related pathways, is a master regulator of various homeostatic processes in joint tissues, as has been demonstrated in a plethora of different cell types in aging and disease associated contexts (1-3).

This previously unrecognized role of *Sirt6* as a regulator of IGF-1 signaling in chondrocytes underscores its importance in overall joint tissue integrity and is a plausible mechanism for the reduction in cartilage ECM gene expression observed in human chondrocytes as well as the severe OA phenotype in our mouse model. Indeed, IGF-1 is known to be a major regulator of articular cartilage ECM integrity by stimulating the synthesis of collagens and proteoglycans (30-32). Furthermore, our prior work in chondrocytes demonstrates that IGF-1 mediated ECM synthesis is dependent on phosphorylation and activation of Akt (33). However, in older and OA chondrocytes, and in chondrocytes treated with oxidative stress inducers to simulate aging conditions, IGF-1/Akt signaling is inhibited leading to a significant reduction in proteoglycan synthesis, activation of pro-catabolic signaling events associated with ECM catabolism such as p38 and ERK phosphorylation, and chondrocyte cell death (26, 27, 33-36). Importantly, our prior work demonstrates that chronic IGF-1 deficiency increases OA severity in older rats, characterized by enhanced proteoglycan loss and cartilage damage when compared to controls (37).

Conversely, activation of Akt is associated with restoration of homeostatic mitochondrial function, increased collagen II synthesis and repression of MMP13 levels which led to protection against cartilage degradation in a rat post-traumatic OA model (38, 39). As such, the discovery of novel strategies aimed at maintaining homeostatic IGF-1/Akt signaling in cartilage during aging and/or in response to joint injury are considered critically important for supporting the chondrocyte phenotype and protecting against OA (40).

In this study, we used adenoviral vectors to overexpress SIRT6 or the commercially available small molecule activator of SIRT6, MDL-800, as tools to enhance SIRT6 activity in human chondrocytes and analyzed Akt signaling. Activation of SIRT6 by both methods led to a robust increase in phosphorylation of Akt and its downstream marker of activity, PRAS40. To our knowledge, this is the first demonstration of SIRT6-mediated activation of Akt in chondrocytes. Furthermore, this finding builds on our prior work showing that SIRT6 overexpression is beneficial to chondrocytes by upregulating antioxidant levels as well as promoting detoxification of oxidative stress levels of H2O2 that are associated with aging and OA (9). MDL-800 has recently been shown to upregulate *COL2A1* and *ACAN* gene expression in chondrocytes (8). In addition, MDL-800 can protect against DMM-induced cartilage damage when administered into the joints of young mice (8). These lines of evidence suggest that MDL-800-mediated activation of SIRT6 may represent a novel and viable therapeutic candidate for OA.

Previous reports have detailed the effect of sirtuins to directly regulate IGF-1/Akt signaling events in several tissues. For example, SIRT1, which is the most studied mammalian sirtuin isoform, mediates deacetylation of Akt to enhance the binding of Akt and PDK1 to PIP3 to enhance IGF-1 signaling in HEK293T cells (41). Furthermore, activation of SIRT1 by several compounds has been shown to attenuate lipopolysaccharide and IL-1β-induced inhibition of Akt phosphorylation to repress inflammatory mediators, enhance cell survival, and promote the synthesis of ECM components such as aggrecan, collagen II and SOX9 in nucleus pulposus cells (42, 43). Although data demonstrating a direct role for SIRT6 to activate IGF-1 signaling is sparse, recent evidence in tumor cell lines demonstrates that overexpression of SIRT6 can deacetylate and phosphorylate Akt to enhance activation of the downstream apoptosis inhibitor protein, XIAP, and promote cell survival (44). These lines of evidence agree with our findings and suggest that SIRT6 may physically interact and deacetylate members of the IGF-1-pathway to promote activation. Elucidating the epigenetic and post-transcriptional effects of SIRT6 on the IGF-1 pathway requires further study.

The observation that IGFBP2 was repressed in *SIRT6* depleted human chondrocytes and mouse cartilage provides important insights into IGF-1 regulation in chondrocytes. Although increased IGFBP levels have been shown to block IGF-1 binding to the IGF receptor (45), several gain- and loss-of-function studies have demonstrated that enhanced IGFBP2 levels increases the phosphorylation and activation of Akt in musculoskeletal tissues (46, 47), which aligns with our findings. Our additional finding that the Wnt antagonists, *SFRP1* and *SFRP4*, were downregulated in *SIRT6* depleted cells suggests that loss of *SIRT6* may lead to aberrant activation of Wnt signaling that could contribute to exacerbation of inflammatory pathways associated with OA, as has been well described in chondrocytes (48). Conversely, *IL1RL1* and *HHIP* gene expression were found to be significantly elevated in *SIRT6* depleted chondrocytes in our study, relative to controls. Upregulation of these genes have been observed in OA tissues and are associated with increased joint inflammation, cytokine release, and OA severity in mouse models of OA (24, 25, 49, 50). Taken together, these lines of evidence add to the hypothesis that loss of *Sirt6* causes a pathological imbalance between pro-anabolic and pro-catabolic signaling events that lead to cartilage degradation and OA. Whether SIRT6 directly, or indirectly regulates these newly identified SIRT6 targets, and in particular IGF-1 and downstream IGF-1 targets, was beyond the scope of the current study, but is a focus of future investigation in cartilage as well as all other joint tissues affected by OA.

There were some limitations in this study. We only used male mice since they are more susceptible to developing OA (51) and our study design required a large number of mice. Future studies would be needed to examine for differences in female mice. We also did not include pain measures, although with the extent of the histological OA noted in the *Sirt6* knockouts we would expect some degree of pain related behavior. Our ongoing research aims to further define the SIRT6 associated mechanisms that drive OA development as well as the potential therapeutic effect of commercially available SIRT6 activators, such as MDL-800 or UBCS039 (52), to protect against OA in other joint tissue cells and multiple animal models of OA in both sexes.

In conclusion, the current study was motivated by several reports, including our own, showing that SIRT6 activity (9) or SIRT6 levels (12) are reduced with age and OA in chondrocytes. We demonstrate herein that cartilage-specific depletion of *Sirt6* increases post-traumatic OA in younger mice and accelerates age-associated OA in older mice. Further, we identify the pro-anabolic IGF-1 pathway as a major target of SIRT6 in chondrocytes. *SIRT6* depletion significantly repressed *IGF-1* levels which is a potential mechanism responsible for the observed reduction of cartilage ECM genes in the absence of *SIRT6*. The development and progression of OA is multi-factorial and multiple homeostatic anabolic and pro-catabolic pathways are altered leading to damage to all joint tissue structures. However, recent studies *in vitro* and *in vivo* demonstrate that SIRT6 can regulate an array of biological processes implicated in aging, healthspan, as well as regeneration (1, 5, 6, 16, 53), which may hold great promise for therapies aimed at slowing, stopping, or reversing the OA process. Thus, targeted strategies that maintain or activate SIRT6 to promote the chondrocyte phenotype and maintain cartilage ECM integrity represent promising avenues for both post-traumatic and age-associated OA therapy as well as other diseases of the joint.

**ACKNOWLEDGEMENTS.** We thank the Gift of Hope Organ and Tissue Donor Network and the donor families for provision of normal human donor tissue. We thank Kathryn Kelley from The University of North Carolina at Chapel Hill for mouse breeding, colony management, and surgeries. We thank Dr. Arkady Margulis and Mrs. Arnavaz Hakimiyan from Rush University Medical Center for tissue procurement. We also thank Alexandra Armstrong, Paula Overn, and Garret Sessions for technical assistance.

**FUNDING AND ADDITIONAL INFORMATION.** This research was conducted while JAC was an Irene Diamond Fund/AFAR Postdoctoral Transition Awardee in Aging. This study was also funded by grants from the National Institute on Aging R03AG070535, R01AG078609 (JC) and R01AG044034 (RFL) and in part by the Klaus Kuettner Endowed Chair for Osteoarthritis Research (SC).

**AUTHOR CONTRIBUTIONS.** This study was conceived by JAC and RFL. Data were acquired by JAC, CK, AC, AL, MMP, RT, and TAF. All authors analyzed and interpreted the data. SC provided human talar tissue. The manuscript was drafted by JAC and all authors contributed to revising the manuscript for scientific content. The final version was approved by all authors.

**ETHICAL APPROVAL INFORMATION.** Animal studies were approved by the University of North Carolina (protocol number; 19-246) and Thomas Jefferson University (protocol number; 02356) Institutional Animal Care and Use Committees following guidelines from the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

**DATA SHARING STATEMENT.** Data are available upon reasonable request. RNA-sequencing data is available at GEO accession GSE235082.

**PATIENT AND PUBLIC INVOLVEMENT STATEMENT.** This study did not involve any human participants.

**REFERENCES**

1. Chang AR, Ferrer CM, Mostoslavsky R. SIRT6, a Mammalian Deacylase with Multitasking Abilities. Physiol Rev. 2020;100(1):145-69.

2. Tasselli L, Zheng W, Chua KF. SIRT6: Novel Mechanisms and Links to Aging and Disease. Trends Endocrinol Metab. 2017;28(3):168-85.

3. Khan RI, Nirzhor SSR, Akter R. A Review of the Recent Advances Made with SIRT6 and its Implications on Aging Related Processes, Major Human Diseases, and Possible Therapeutic Targets. Biomolecules. 2018;8(3).

4. Mostoslavsky R, Chua KF, Lombard DB, Pang WW, Fischer MR, Gellon L, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell. 2006;124(2):315-29.

5. Roichman A, Kanfi Y, Glazz R, Naiman S, Amit U, Landa N, et al. SIRT6 Overexpression Improves Various Aspects of Mouse Healthspan. J Gerontol A Biol Sci Med Sci. 2017;72(5):603-15.

6. Roichman A, Elhanati S, Aon MA, Abramovich I, Di Francesco A, Shahar Y, et al. Restoration of energy homeostasis by SIRT6 extends healthy lifespan. Nat Commun. 2021;12(1):3208.

7. Kanfi Y, Naiman S, Amir G, Peshti V, Zinman G, Nahum L, et al. The sirtuin SIRT6 regulates lifespan in male mice. Nature. 2012;483(7388):218-21.

8. Ji ML, Jiang H, Li Z, Geng R, Hu JZ, Lin YC, et al. Sirt6 attenuates chondrocyte senescence and osteoarthritis progression. Nat Commun. 2022;13(1):7658.

9. Collins JA, Kapustina M, Bolduc JA, Pike JFW, Diekman BO, Mix K, et al. Sirtuin 6 (SIRT6) regulates redox homeostasis and signaling events in human articular chondrocytes. Free Radic Biol Med. 2021;166:90-103.

10. Loeser RF, Collins JA, Diekman BO. Ageing and the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016;12(7):412-20.

11. Collins JA, Diekman BO, Loeser RF. Targeting aging for disease modification in osteoarthritis. Curr Opin Rheumatol. 2018;30(1):101-7.

12. Wu Y, Chen L, Wang Y, Li W, Lin Y, Yu D, et al. Overexpression of Sirtuin 6 suppresses cellular senescence and NF-kappaB mediated inflammatory responses in osteoarthritis development. Sci Rep. 2015;5:17602.

13. Chen J, Chen S, Cai D, Wang Q, Qin J. The role of Sirt6 in osteoarthritis and its effect on macrophage polarization. Bioengineered. 2022;13(4):9677-89.

14. Nagai K, Matsushita T, Matsuzaki T, Takayama K, Matsumoto T, Kuroda R, et al. Depletion of SIRT6 causes cellular senescence, DNA damage, and telomere dysfunction in human chondrocytes. Osteoarthritis Cartilage. 2015;23(8):1412-20.

15. Yang J, Zhou Y, Liang X, Jing B, Zhao Z. MicroRNA-486 promotes a more catabolic phenotype in chondrocyte-like cells by targeting SIRT6 : possible involvement in cartilage degradation in osteoarthritis. Bone Joint Res. 2021;10(7):459-66.

16. Ailixiding M, Aibibula Z, Iwata M, Piao J, Hara Y, Koga D, et al. Pivotal role of Sirt6 in the crosstalk among ageing, metabolic syndrome and osteoarthritis. Biochem Biophys Res Commun. 2015;466(3):319-26.

17. Woo SJ, Noh HS, Lee NY, Cheon YH, Yi SM, Jeon HM, et al. Myeloid sirtuin 6 deficiency accelerates experimental rheumatoid arthritis by enhancing macrophage activation and infiltration into synovium. EBioMedicine. 2018;38:228-37.

18. Glasson SS, Blanchet TJ, Morris EA. The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. Osteoarthritis Cartilage. 2007;15(9):1061-9.

19. Loeser RF, Coryell PR, Armstrong AR, Collins JA, Gopalakrishnan P, McDermott KA, et al. Overexpression of Peroxiredoxin 3 in Cartilage Reduces the Severity of Age-Related Osteoarthritis But Not Surgically Induced Osteoarthritis in Mice. ACR Open Rheumatol. 2022;4(5):441-6.

20. McNulty MA, Loeser RF, Davey C, Callahan MF, Ferguson CM, Carlson CS. A Comprehensive Histological Assessment of Osteoarthritis Lesions in Mice. Cartilage. 2011;2(4):354-63.

21. Ewart D, Harper L, Gravely A, Miller RA, Carlson CS, Loeser RF. Naturally occurring osteoarthritis in male mice with an extended lifespan. Connect Tissue Res. 2020;61(1):95-103.

22. Armstrong AR, Carlson CS, Rendahl AK, Loeser RF. Optimization of histologic grading schemes in spontaneous and surgically-induced murine models of osteoarthritis. Osteoarthritis Cartilage. 2021;29(4):536-46.

23. Loeser RF, Olex AL, McNulty MA, Carlson CS, Callahan MF, Ferguson CM, et al. Microarray analysis reveals age-related differences in gene expression during the development of osteoarthritis in mice. Arthritis Rheum. 2012;64(3):705-17.

24. Sugita S, Hosaka Y, Okada K, Mori D, Yano F, Kobayashi H, et al. Transcription factor Hes1 modulates osteoarthritis development in cooperation with calcium/calmodulin-dependent protein kinase 2. Proc Natl Acad Sci U S A. 2015;112(10):3080-5.

25. Lin AC, Seeto BL, Bartoszko JM, Khoury MA, Whetstone H, Ho L, et al. Modulating hedgehog signaling can attenuate the severity of osteoarthritis. Nat Med. 2009;15(12):1421-5.

26. Collins JA, Wood ST, Nelson KJ, Rowe MA, Carlson CS, Chubinskaya S, et al. Oxidative Stress Promotes Peroxiredoxin Hyperoxidation and Attenuates Pro-survival Signaling in Aging Chondrocytes. J Biol Chem. 2016;291(13):6641-54.

27. Collins JA, Arbeeva L, Chubinskaya S, Loeser RF. Articular chondrocytes isolated from the knee and ankle joints of human tissue donors demonstrate similar redox-regulated MAP kinase and Akt signaling. Osteoarthritis Cartilage. 2019;27(4):703-11.

28. Huang Z, Zhao J, Deng W, Chen Y, Shang J, Song K, et al. Identification of a cellularly active SIRT6 allosteric activator. Nat Chem Biol. 2018;14(12):1118-26.

29. Shang JL, Ning SB, Chen YY, Chen TX, Zhang J. MDL-800, an allosteric activator of SIRT6, suppresses proliferation and enhances EGFR-TKIs therapy in non-small cell lung cancer. Acta Pharmacol Sin. 2020.

30. Guenther HL, Guenther HE, Froesch ER, Fleisch H. Effect of insulin-like growth factor on collagen and glycosaminoglycan synthesis by rabbit articular chondrocytes in culture. Experientia. 1982;38(8):979-81.

31. Luyten FP, Hascall VC, Nissley SP, Morales TI, Reddi AH. Insulin-like growth factors maintain steady-state metabolism of proteoglycans in bovine articular cartilage explants. Arch Biochem Biophys. 1988;267(2):416-25.

32. Osborn KD, Trippel SB, Mankin HJ. Growth factor stimulation of adult articular cartilage. J Orthop Res. 1989;7(1):35-42.

33. Starkman BG, Cravero JD, Delcarlo M, Loeser RF. IGF-I stimulation of proteoglycan synthesis by chondrocytes requires activation of the PI 3-kinase pathway but not ERK MAPK. Biochem J. 2005;389(Pt 3):723-9.

34. Yin W, Park JI, Loeser RF. Oxidative stress inhibits insulin-like growth factor-I induction of chondrocyte proteoglycan synthesis through differential regulation of phosphatidylinositol 3-Kinase-Akt and MEK-ERK MAPK signaling pathways. J Biol Chem. 2009;284(46):31972-81.

35. Loeser RF, Gandhi U, Long DL, Yin W, Chubinskaya S. Aging and oxidative stress reduce the response of human articular chondrocytes to insulin-like growth factor 1 and osteogenic protein 1. Arthritis Rheumatol. 2014;66(8):2201-9.

36. Collins JA, Wood ST, Bolduc JA, Nurmalasari NPD, Chubinskaya S, Poole LB, et al. Differential peroxiredoxin hyperoxidation regulates MAP kinase signaling in human articular chondrocytes. Free Radic Biol Med. 2019;134:139-52.

37. Ekenstedt KJ, Sonntag WE, Loeser RF, Lindgren BR, Carlson CS. Effects of chronic growth hormone and insulin-like growth factor 1 deficiency on osteoarthritis severity in rat knee joints. Arthritis Rheum. 2006;54(12):3850-8.

38. Yao X, Zhang J, Jing X, Ye Y, Guo J, Sun K, et al. Fibroblast growth factor 18 exerts anti-osteoarthritic effects through PI3K-AKT signaling and mitochondrial fusion and fission. Pharmacol Res. 2019;139:314-24.

39. Rosa SC, Rufino AT, Judas F, Tenreiro C, Lopes MC, Mendes AF. Expression and function of the insulin receptor in normal and osteoarthritic human chondrocytes: modulation of anabolic gene expression, glucose transport and GLUT-1 content by insulin. Osteoarthritis Cartilage. 2011;19(6):719-27.

40. Wen C, Xu L, Xu X, Wang D, Liang Y, Duan L. Insulin-like growth factor-1 in articular cartilage repair for osteoarthritis treatment. Arthritis Res Ther. 2021;23(1):277.

41. Sundaresan NR, Pillai VB, Wolfgeher D, Samant S, Vasudevan P, Parekh V, et al. The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci Signal. 2011;4(182):ra46.

42. Kuai J, Zhang N. Upregulation of SIRT1 by Evodiamine activates PI3K/AKT pathway and blocks intervertebral disc degeneration. Mol Med Rep. 2022;26(2).

43. Qi W, Ren D, Wang P, Song Z, Wu H, Yao S, et al. Upregulation of Sirt1 by tyrosol suppresses apoptosis and inflammation and modulates extracellular matrix remodeling in interleukin-1beta-stimulated human nucleus pulposus cells through activation of PI3K/Akt pathway. Int Immunopharmacol. 2020;88:106904.

44. Zhou HZ, Zeng HQ, Yuan D, Ren JH, Cheng ST, Yu HB, et al. NQO1 potentiates apoptosis evasion and upregulates XIAP via inhibiting proteasome-mediated degradation SIRT6 in hepatocellular carcinoma. Cell Commun Signal. 2019;17(1):168.

45. Allard JB, Duan C. IGF-Binding Proteins: Why Do They Exist and Why Are There So Many? Front Endocrinol (Lausanne). 2018;9:117.

46. Shen X, Xi G, Maile LA, Wai C, Rosen CJ, Clemmons DR. Insulin-like growth factor (IGF) binding protein 2 functions coordinately with receptor protein tyrosine phosphatase beta and the IGF-I receptor to regulate IGF-I-stimulated signaling. Mol Cell Biol. 2012;32(20):4116-30.

47. Xi G, Wai C, DeMambro V, Rosen CJ, Clemmons DR. IGFBP-2 directly stimulates osteoblast differentiation. J Bone Miner Res. 2014;29(11):2427-38.

48. Wang Y, Fan X, Xing L, Tian F. Wnt signaling: a promising target for osteoarthritis therapy. Cell Commun Signal. 2019;17(1):97.

49. Xu WD, Zhang M, Zhang YJ, Ye DQ. IL-33 in rheumatoid arthritis: potential role in pathogenesis and therapy. Hum Immunol. 2013;74(9):1057-60.

50. Shuang F, Zhou Y, Hou SX, Zhu JL, Liu Y, Zhang CL, et al. Indian Hedgehog signaling pathway members are associated with magnetic resonance imaging manifestations and pathological scores in lumbar facet joint osteoarthritis. Sci Rep. 2015;5:10290.

51. Ma HL, Blanchet TJ, Peluso D, Hopkins B, Morris EA, Glasson SS. Osteoarthritis severity is sex dependent in a surgical mouse model. Osteoarthritis Cartilage. 2007;15(6):695-700.

52. Iachettini S, Trisciuoglio D, Rotili D, Lucidi A, Salvati E, Zizza P, et al. Pharmacological activation of SIRT6 triggers lethal autophagy in human cancer cells. Cell Death Dis. 2018;9(10):996.

53. Koo JH, Jang HY, Lee Y, Moon YJ, Bae EJ, Yun SK, et al. Myeloid cell-specific sirtuin 6 deficiency delays wound healing in mice by modulating inflammation and macrophage phenotypes. Exp Mol Med. 2019;51(4):1-10.

**FIGURE LEGENDS.**

**Figure 1. The effect of *Sirt6* deficiency on OA severity after DMM surgery.** *Sirt6* intact and *Sirt6* deficient (cKO) mice received sham or DMM surgery at 16 weeks of age and OA severity was analyzed at 6- and 10-weeks post-DMM surgery by histology and µCT. (**A,B**) Representative images of H&E stained midcoronal sections showing the MTP and MFC from *Sirt6* intact and *Sirt6* cKO mice at 6- and 10-weeks post DMM surgery. (**C,D**) Summed (MTP, MFC, LTP, LFC) Articular Cartilage Structure (ACS) and toluidine blue scores, summed (MTP, LTP) osteophyte scores, and synovial hyperplasia scores (medial side) at 6- and 10-weeks post-DMM surgery. Black arrows indicate areas of complete articular cartilage loss. MFC=medial femoral condyle, MTP=medial tibial plateau, LFC=lateral femoral condyle, LTP=lateral tibial plateau. (**E-F**) Representative 3-D Micro-CT reconstructions of knee joints from representative sham, *Sirt6* intact and *Sirt6* cKO mice at 6- and 10-weeks post DMM surgery. Upper panels show transverse images of the tibial plateau and lower panels show images of the whole joint. (**G-H**) Micro-CT analysis of subchondral bone changes (BV/TV, Tb.Th, Tb.Sp, SCBP.Th) on the medial tibial plateaus of *Sirt6* intact and *Sirt6* cKO mice (DMM and sham groups) at 6- and 10-weeks post-DMM surgery. (**I**) Micro-CT analysisof max osteophyte area and osteophyte volume on the MTP of *Sirt6* intact and *Sirt6* cKO mice (DMM groups only) at 6 weeks and (**J**) 10 weeks post-DMM surgery. Individual data points are presented with mean ± standard deviation (SD). Significant differences between groups were detected by Mann-Whitney test comparing sham and DMM groups for each genotype (**A-H**) or t-test (**I,J**). Exact *p-*values are presented.

**Figure 2. The effect of *Sirt6* deficiency on OA severity during aging.** *Sirt6* intact and *Sirt6* deficient (cKO) mice were aged to 12- and 18-months of age and spontaneous OA was analyzed by histology and µCT. (**A,B**) Representative images of H&E stained midcoronal sections showing the medial tibial plateau and medial femoral condyle from *Sirt6* intact and *Sirt6* cKO mice at 12- and 18-months of age. (**C,D**) Summed (MTP, MFC, LTP, LFC) Articular Cartilage structure (ACS) and toluidine blue scores, summed (MTP, LTP) osteophyte scores, and synovial hyperplasia scores (medial side) at 12- and 18-months of age. Black arrows indicate areas of complete articular cartilage loss. (**E**) Micro-CT analysis of subchondral bone changes (BV/TV, Tb.Th, Tb.Sp, SCBP.Th) on the medial tibial plateaus of *Sirt6* intact and *Sirt6* cKO mice at 12-months and (**F**) 18-months of age. Individual data points are presented with mean ± standard deviation (SD). Significant differences between groups were detected by unpaired *t-*test. Exact *p-*values are presented.

**Figure 3. RNA-sequencing analysis of *Sirt6* depleted human chondrocytes.** To assess *SIRT6*-mediated transcriptional regulation, RNA-sequencing was conducted on primary human chondrocytes nucleofected (72 hours) with siRNA to *Sirt6* (siSirt6, *Sirt6* knockdown) and compared to cells nucleofected with a scrambled siRNA as a control (siCtrl). (**A**) Heatmap showing significant differentially expressed genes identified in our dataset. Selected upregulated and downregulated genes are highlighted when comparing *Sirt6* depleted cells to controls. (**B**) Gene ontology (GO) enrichment showing downregulated processes in *Sirt6* depleted cells, when compared to control, are presented. (**C**) RT-PCR was conducted on human chondrocytes to validate expression of selected genes found in the RNA-sequencing dataset. Significant differences between groups were detected by paired *t-*test. Exact *p-*values are presented (**D**) Upstream Regulator Analysis using the Ingenuity Pathway Analysis tool showing the effect of downregulated *IGF-1* expression on its targets.

**Figure 4. SIRT6 regulates IGF-1 signaling in chondrocytes.** (**A**) Femoral caps from *Sirt6* intact and *Sirt6* deficient mice were treated with 4- Hydroxytamoxifen to activate Cre-mediated recombination *ex vivo*. Protein levels of IGFBP2, phospho-Akt (Ser473) and SIRT6 were assessed by immunoblotting (n=3). (**B**) Immunohistochemistry to detect IGF-1 levels was performed on *Sirt6* intact and *Sirt6* deficient mouse joint tissue sections derived from sham control mice from our DMM study (n=5), and percentage IGF-1 positively stained cells were quantified. **(C)** Primary non-OA older human chondrocytes were transduced with an adenoviral vector to overexpress SIRT6 or an empty vector control for 24 hours prior to immunoblotting for phospho-Akt (Ser473, Thr308), phospho-PRAS40, and SIRT6 (n=5). (**D**) Primary non-OA human chondrocytes were treated with MDL-800 (12.5 µM) for 0-24 hours prior to immunoblotting for phospho-Akt (Ser473), phospho-PRAS40, and SIRT6 (n=4). Presented immunoblots are representative and protein bands were normalized to total protein or housekeeping proteins as indicated. Individual data points are presented with mean ± standard deviation (SD). Significant differences were detected by *t-*test (A-C) or two-way ANOVA (D). \**p=*<0.05, \*\**p=*<0.01, \*\*\**p=*<0.001, *p=*<0.0001.

**KEY MESSAGES**

**What is already known on this topic?**

* Sirt6 activity significantly declines in aging chondrocytes which promotes catabolic signaling events implicated in OA development and progression.
* Sirt6 regulates multiple pathways necessary for chondrocyte homeostasis but the effect of Sirt6 deficiency on OA development *in vivo* and the specific Sirt6-associated mechanisms responsible remain largely unexplored.

**What this study adds.**

* Cartilage-specific Sirt6 deficiency enhances post-traumatic OA and accelerates age-associated OA in mice
* Depletion of chondrocyte Sirt6 significantly represses IGF-1 signaling and downregulates multiple cartilage ECM components including COL2A1.
* Genetic and pharmacological activation of Sirt6 promotes pro-survival and pro-anabolic IGF-1/Akt activation in human chondrocytes.

**How this study might affect research, practice, or policy.**

* The SIRT6/IGF-1 signaling axis is an important mediator of cartilage integrity and the chondrocyte phenotype.
* Targeted therapies that promote chondrocyte SIRT6 activity during aging and in response to injury represents a novel strategy to reduce OA severity.